⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKTX News
Akari Therapeutics plc ADR (0.01 USD)
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
globenewswire.com
AKTX
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
globenewswire.com
AKTX
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
globenewswire.com
AKTX
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
globenewswire.com
AKTX
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
globenewswire.com
AKTX
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
globenewswire.com
AKTX
Form 8-K
sec.gov
AKTX